Imvotamab by IGM Biosciences for Rheumatoid Arthritis: Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Rheumatoid Arthritis.
Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Rheumatoid Arthritis.
What's Your Reaction?
